Hypercoagulable states in primary upper-extremity deep vein thrombosis

Archives of Internal Medicine

Volumn 160, Issue 3, 2000, Pages 382-386

  Héron, Emmanuel ^a,b   Lozinguez, Olivier ^a   Alhenc Gelas, Martine ^b   Emmerich, Joseph ^a   Fiessinger, Jean Noël ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARM; ARTICLE; BLOOD CLOTTING TEST; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PREVALENCE; PRIORITY JOURNAL;

EID: 0141726630     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.3.382     Document Type: Article

References (19)

1. Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: the VITA project. Thromb Haemost. 1997;78:636-640.
2. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, and the EMET group. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost. 1997;77:444-451.
3. Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis: risk factors, diagnosis, and complications. Arch Intern Med. 1997;157:57-62.
4. Ruggeri M, Castaman G, Tosetto A, Rodeghiero F. Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs. Blood Coagul Fibrinolysis. 1997;8:191-194.
5. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci P. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med. 1997;126:707-711.
6. Gloviczki P, Kazmier FJ, Hollier LH. Axillary subclavian venous occlusion: the morbidity of a nonlethal disease. J Vasc Surg. 1986;4:333-337.
7. Working Group on Haemostasis of the Société Française de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost, 1993;70:781-786.
8. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagul Fibrinolysis. 1995;6:245-249.
9. Alhenc-Gelas M, Arnaud E, Nicaud V, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost. 1999;81:506-510.
10. Mozes M, Bogokowsky H, Antebi E, et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophms. Lancet. 1965;2:1213-1215.
11. Lindblad B, Tengborn L, Bergqvist D. Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg. 1988;2:161-165.
12. Elliott G. Upper-extremity deep vein thrombosis. Lancet. 1997;349:1188-1189.
13. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995; 346:1133-1134.
14. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20:231-236.
15. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific rates of thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528-531.
16. Mills MS, Eddowes HA, Fox R, Wardle PG. Subclavian vein thrombosis: a late complication of ovarian hyperstimulation syndrome. Hum Reprod. 1992;7:370-371.
17. Hocke C, Guyon F, Dulucq MC, Grenier N, Papaxanthos A, Leng JJ. Accidents thrombo-emboliques et hyperstimulation ovarienne. J Gynecol Obstet Biol Reprod (Paris). 1995;24:691-696.
18. Stewart JA, Hamilton PJ, Murdoch AP. Upper limb thrombosis associated with assisted conception treatment. Hum Reprod. 1997;12:2174-2175.
19. Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med. 1998; 3:67-73.